ATYR — aTYR PHARMA INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1339970 ·
Last close
$0.53
Market Cap
$51.99M
52W High
$0.70
52W Low
$0.44
ADV30
923,913
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,881,000 | -10,309,000 | 69,825,000 | 16,160,000 | 21,231,000 |
| Mar 2026 | 0 | — | -11,436,000 | -10,791,000 | 79,654,000 | 10,008,000 | 21,913,000 |
| Dec 2025 | 0 | — | -14,796,000 | -13,963,000 | 93,003,000 | 10,743,000 | 25,715,000 |
| Sep 2025 | 190,000 | — | -26,745,000 | -25,744,000 | 106,652,000 | 6,150,000 | 26,608,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,083,000
Investing CF
$10,861,000
Financing CF
$47,241,000
CapEx
$-231,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-616,955,000
Inventory
—
Receivables
$477,000
ST Investments
$56,505,000
EBIT TTM
$-73,290,000
Pretax Income TTM
$-70,034,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$190,000
EBITDA
$-63,197,000
Free Cash Flow
$-31,708,250
Enterprise Value
$2,877,843
Total Cash
$57,418,000
Total Debt
$11,299,000
Shares Out
98,087,425
Trailing EPS
$-0.63
Book Value
$0.50
ROE
-98.7%
ROA
-46.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 190,000 | -77,627,000 | -74,118,000 | 93,003,000 | 25,715,000 | — | -61,986,000 |
| Dec 2024 | 235,000 | -67,914,000 | -64,023,000 | 96,830,000 | 26,998,000 | — | -69,119,000 |
| Dec 2023 | 353,000 | -54,919,000 | -50,389,000 | 120,653,000 | 30,183,000 | — | -33,221,000 |
| Dec 2022 | 10,386,000 | -46,404,000 | -45,338,000 | 95,786,000 | 24,502,000 | — | -41,886,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-16,306,000
OpCashFlow TTM
$0
Assets (Latest)
$96,830,000
Forward EPS
$-0.46
Max Pain — expiry 2027-01-15
max pain strike: $0.50 · spot: $0.53 · call oi: 5,170 · put oi: 297
Expected Move to 2027-01-15:
±$0.30
(56.60%) —
implied range
$0.23 –
$0.83
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TIL | Instil Bio, Inc. | $52.97M | $7.81 | — |
| BKHA | Black Hawk Acquisition Corp | $49.39M | $11.89 | — |
| TCRX | TScan Therapeutics, Inc. | $48.82M | $0.80 | — |
| GNTA | Genenta Science S.p.A. | $55.45M | $1.15 | — |
| MGX | Metagenomi Therapeutics, Inc. | $45.71M | $1.21 | — |
News headlines (Yahoo Finance, 1h cache)
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans
2026-08-07 20:39 · Yahoo
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
2026-08-07 20:01 · Yahoo
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
2026-07-15 12:00 · Yahoo
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
2026-05-15 12:00 · Yahoo
aTyr Pharma to Participate in Upcoming Investor Conferences
2026-05-13 20:01 · Yahoo
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial
2026-05-12 00:09 · Yahoo
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
2026-05-11 20:01 · Yahoo
What It Means To Hold Moderna Stock In A Crash
2026-07-13 13:12 · Yahoo
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
2026-06-26 12:35 · Yahoo
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
2026-06-23 12:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.